Drug Master Files, manufacturer listings, and Electronic Common Technical Document (eCTD) submissions are foundational to regulatory compliance. Yet even experienced regulatory, quality, and operations...
The global Unique Device Identification (UDI) landscape is entering a critical enforcement phase — and 2026 will be a challenging year for medical device manufacturers operating in the European Union...
The FDA’s final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” establishes a uniform 12-digit format for FDA-assigned National Drug Codes (NDCs) ...
UDI product data is now due for specific scenarios (enforced as of December 8, 2022). Class I and Unclassified medical devices that are required to be labeled with a UDI code must submit product data...
LexisNexis Life Sciences Solutions and ONIX expand strategic alliance to guide pharma customers to market faster Professionals in the life sciences industry rely on unique regulatory affairs expertise...
Following a lengthy period of anticipation, Health Canada has released Draft Guidance Document Preparation of the Product Monograph in Extensible Markup Language (XML) Format and sample files. Along with the draft guidance, Health Canada has opened a comment period, scheduled to conclude on November 5, 2023. According to Health Canada, the purpose of this guidance is to assist sponsors in developing a product monograph in the Extensible Markup Language format (XML PM).
The latest round of revisions to the guidance are based on internal and working group feedback. To request a copy of the draft guidance and sample files, email: no-reply.ereview.non-reponse@hc-sc.gc.ca.
In the draft guidance, Health Canada states the following background:
The PM provides the necessary information for the safe and effective use of a drug product. It is comprised of three major sections, two of which target health care professionals. The third section targets the consumer. The PM is submitted by sponsors for review in a MSWord format. Once approved, the document is converted to PDF and published to the DPD Online and the Drug and Health Product Portal.
The XML PM represents a major step towards Health Canada’s goal of improving access to drug information for Canadians. The structure and controlled vocabulary will enable benefits not previously possible – consistency, searchability and innovation. Approved XML PMs will be stored in a fully searchable XML database. Stylesheets will enable transformation into a human readable format. This format will enable the appropriate data to be provided in ways that are most relevant to different user groups, including providing Canadian pharmacies reliable access to the Canadian approved Patient Medicinal Information. It will also facilitate further collaboration with our international partners related to drug clinical trials, risk assessments and potential shortages.
The scope of this guidance and the use of the XML format for PMs is limited to the following product lines:
The following product lines are out of scope:
LexisNexis Life Sciences Solutions, an industry leader in pharmaceutical structured files, is offering a Health Canada solution that includes data validation, XML-PM build and check, version control, storage and reporting. To learn more about LexisNexis Life Sciences Health Canada services, see our Health Canada XML PM webinar or contact us below.
Contact us